Herbal and prescription weight loss products: awareness among pharmacists about efficacy and safety

2016 ◽  
Vol 46 (4) ◽  
pp. 331-337
Author(s):  
Areeg A. A. Shamsher ◽  
Nada Nadeem ◽  
Verda Nadeem ◽  
Khawla O. Mutib ◽  
Nasiba O. Mutib ◽  
...  
Keyword(s):  
Weight Loss ◽  
Efficacy And Safety

The Efficacy and Safety of Auriculotherapy for Weight Loss: A Systematic Review and Meta-Analysis

2021 ◽  
pp. 101402
Author(s):  
Liping Chen ◽  
Junpeng Yao ◽  
Zhihan Chen ◽  
Xiaoyu Hu ◽  
Zijiao Liu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Weight Loss ◽  
Meta Analysis ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of the weight-loss drug rimonabant

The Lancet ◽  
2008 ◽  
Vol 371 (9612) ◽  
pp. 555 ◽  
Author(s):  
Jean-Pierre Després ◽  
Luc Van Gaal ◽  
Xavier Pi-Sunyer ◽  
André Scheen
Keyword(s):  
Weight Loss ◽  
Efficacy And Safety ◽  
Weight Loss Drug

scholarly journals EFFICACY AND SAFETY OF STANDARDIZED CINNAMON BARK EXTRACT FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED WEIGHT LOSS AND ALOPECIA IN PATIENTS WITH BREAST CANCER: A RANDOMIZED, DOUBLE-BLIND, AND PLACEBO-CONTROLLED STUDY

2019 ◽  
pp. 163-168
Author(s):  
AJAY MEHTA ◽  
SUCHITRA MEHTA ◽  
PRASAD THAKURDESAI
Keyword(s):  
Breast Cancer ◽  
Weight Loss ◽  
Side Effects ◽  
Cancer Patients ◽  
Outcome Measures ◽  
Bark Extract ◽  
Efficacy And Safety ◽  
Breast Cancer Patients ◽  
Double Blind ◽  
Cinnamon Bark

Objective: The objective of the study was to evaluate the effects of IND02 (standardized Cinnamon bark extract) supplementation for the prevention of side effects of cancer chemotherapy in female patients with breast cancer. Methods: The study was conducted using double-blind, placebo-controlled design in 34 female breast cancer patients during the first 4 consecutive 21-day cycles of the standard chemotherapy regimen. The active treatment (IND02 capsules, 400 mg, one capsule, and thrice a day) or matching placebo was orally administrated in randomized (1:1 ratio) patients. The efficacy outcome measures were reduction in chemotherapy-induced weight loss, alopecia (hair fall), and other side effects. The safety outcome measures were hematology, ECG, vital signs, adverse event monitoring, and laboratory safety measurements. Results: The patients on the treatment with IND02 had shown significant protection from chemotherapy-induced severe weight loss (cachexia) and alopecia (reduced hair density and % hairs in the anagen phase, and increased % hairs in telogen phase) which was seen in the placebo group. IND02 treatment was found safe and well-tolerated during the study. Conclusion: Concomitant use of IND02 in breast cancer patients during breast cancer chemotherapy showed a clinical promise regarding efficacy and safety in preventing chemotherapy-induced weight loss and alopecia.

scholarly journals The Efficacy and Safety of Sibutramine for Weight Loss

2004 ◽  
Vol 164 (9) ◽  
pp. 994 ◽  
Author(s):  
David E. Arterburn ◽  
Paul K. Crane ◽  
David L. Veenstra
Keyword(s):  
Weight Loss ◽  
Efficacy And Safety

Efficacy and Safety of Ephedra and Ephedrine for Weight Loss and Athletic Performance

JAMA ◽  
2003 ◽  
Vol 289 (12) ◽  
pp. 1537 ◽  
Author(s):  
Paul G. Shekelle ◽  
Mary L. Hardy ◽  
Sally C. Morton ◽  
Margaret Maglione ◽  
Walter A. Mojica ◽  
...  
Keyword(s):  
Weight Loss ◽  
Athletic Performance ◽  
Efficacy And Safety

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

The Lancet ◽  
2007 ◽  
Vol 370 (9600) ◽  
pp. 1706-1713 ◽  
Author(s):  
Robin Christensen ◽  
Pernelle Kruse Kristensen ◽  
Else Marie Bartels ◽  
Henning Bliddal ◽  
Arne Astrup
Keyword(s):  
Weight Loss ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Randomised Trials ◽  
Weight Loss Drug

203 THE EFFICACY AND SAFETY OF A PROCEDURELESS GASTRIC BALLOON FOR WEIGHT LOSS: A SYSTEMATIC REVIEW AND META-ANALYSIS

2020 ◽  
Vol 158 (6) ◽  
pp. S-37
Author(s):  
Veeravich Jaruvongvanich ◽  
Azizullah Beran ◽  
Matar Reem ◽  
Kornpong Vantanasiri ◽  
Sikarin Upala
Keyword(s):  
Systematic Review ◽  
Weight Loss ◽  
Meta Analysis ◽  
Gastric Balloon ◽  
Efficacy And Safety

PP012 Efficacy And Safety Of The ELIPSE Gastric Balloon For Weight Loss

2017 ◽  
Vol 33 (S1) ◽  
pp. 72-73
Author(s):  
Luis María Sánchez-Gómez ◽  
Setefilla Luengo-Matos ◽  
Mar Polo-Desantos ◽  
Juan Pablo Chalco Orrego
Keyword(s):  
Quality Of Life ◽  
Weight Loss ◽  
New Technologies ◽  
Cochrane Library ◽  
Gastric Balloon ◽  
Efficacy And Safety ◽  
Early Assessment ◽  
The Mean ◽  
The Impact

INTRODUCTION:Conventional gastric balloons for weight loss require endoscopy for placement and removal. The ELIPSETM is a new gastric balloon designed for weight loss that is swallowed and does not require endoscopy or anesthesia. The device is designed to remain in the stomach and be expelled after a predetermined time of 4 months. The objective of this work is to assess the efficacy and safety of the ELIPSETM procedureless gastric balloon for weight loss.METHODS:The ELIPSETM procedureless gastric balloon was identified by the early Awareness and Alert System, “SINTESIS-new technologies,” of The Instituto De Salud Carlos III (AETS-ISCIII). An early assessment of the technology was conducted. The searched databases were: MEDLINE (PubMed), Centre for Reviews and Dissemination, and the Cochrane Library. Clinical studies using the device published in any language until 10 January 2017 were reviewed.RESULTS:A prospective, non-randomized, open label study supported by industry was retrieved. Thirty-four patients were enrolled. Six patients treated with an experimental device were excluded. Twenty-eight patients successfully swallowed the device. No endoscopy or anesthesia was required. All devices were excreted safely. Of the twenty-five patients finally studied, the mean percent total body weight loss was 10 percent (95 percent Confidence Interval, CI 7.3–12.7) and the mean waist circumference was reduced by 8.4cm (95 percent CI 5.7-11.8) at 4 months. Improvements were also seen in metabolic parameters (HbA1c, Low density lipoprotein, triglycerides and blood pressure). All aspects of quality of life measured by the Impact of Weight on Quality of Life (IWQoL) questionnaire demonstrated significant improvements. About safety, there were no serious adverse events or serious adverse device effects, however 64 percent of patients had vomiting, 54 percent experienced nausea, 25 percent had abdominal pain and 2 patients were excluded because of symptoms.CONCLUSIONS:The ELIPSETM gastric balloon for weight loss seems to be an effective therapy with an acceptable safety profile. However it would be necessary to continue further studies to confirm these results, including comparative studies with current treatments.

Sign in / Sign up

Export Citation Format

Share Document